CJC-1295
Also known as CJC-1295 DAC, Modified GRF (1-29)
A long-acting GHRH analog studied to raise growth hormone, often paired with ipamorelin.
Medically reviewed by Dr. Jonathan Snipes, MD
Reviewed for clinical accuracy · Last reviewed July 22, 2026 · Review policy
Quick answer
CJC-1295 is a long-acting GHRH analog designed to stimulate the body's own growth-hormone release. Early human studies show it raises growth hormone and IGF-1, but it is not FDA-approved, outcome data is limited, and it is prohibited in sport. It is frequently paired with ipamorelin.
- Drug class
- Long-acting GHRH analog
- FDA status
- Not approved
- Route
- Subcutaneous injection
- Evidence grade
- C (Emerging Human Data)
- Banned in sport
- Yes (WADA)
Key takeaways
- →CJC-1295 is a GHRH analog engineered for a longer duration of action, raising growth hormone and IGF-1.
- →Early human pharmacokinetic studies confirm it increases GH/IGF-1; clinical outcome data is limited.
- →It is commonly combined with ipamorelin, a growth-hormone-releasing peptide, in community protocols.
- →It is not FDA-approved and is prohibited in sport.
CJC-1295 is a growth-hormone-releasing hormone analog engineered to last longer in the body than natural GHRH or sermorelin. It has some genuine early human data confirming it raises growth hormone, which places it a notch above purely preclinical compounds, but it stops short of the trial base needed to establish real-world benefit and safety.
How CJC-1295 works
Like other GHRH analogs, CJC-1295 stimulates the pituitary to release growth hormone. Its distinguishing feature is a modification (and, in the DAC version, binding to albumin) that extends its half-life, producing a more sustained elevation in GH and IGF-1. This is why it is often stacked with a shorter-acting GH-releasing peptide like ipamorelin.
What the evidence shows, by use
Each use is graded on the same A-E scale, based on human-trial quality rather than popularity.
Raising GH / IGF-1
CEmerging Human DataEarly human pharmacokinetic studies show increased GH and IGF-1; this is the best-supported effect.
Body composition / anti-aging / recovery
DPreclinical OnlyPopular goals with little controlled human outcome evidence for CJC-1295 specifically.
Dosing
CJC-1295 is not FDA-approved and has no official dose. Community protocols, often combined with ipamorelin, are extrapolated rather than trial-validated, and much market supply is research-grade material of unverified quality. Any use should be through a licensed clinician and a legitimate pharmacy.
Side effects
- •Injection-site reactions · Common
- •Flushing · Reported
- •Water retention · Reported
- •Headache or tingling · Reported
Legal & regulatory status
CJC-1295 is not FDA-approved and is prohibited in sport. It is sold and compounded outside a formal approval.
Is CJC-1295legal? Full regulatory status →Where to get it: TeleRanked independently ranks the telehealth providers that offer clinician-prescribed peptides. See our Peptide Therapy rankings. We rank providers, we do not sell compounds, and rankings are never for sale.
Frequently asked questions
What is CJC-1295 used with?+
It is commonly combined with ipamorelin, a growth-hormone-releasing peptide, in community protocols, on the theory that the two act through complementary pathways.
Is CJC-1295 FDA-approved?+
No. CJC-1295 is not FDA-approved and is prohibited in sport.
How we grade evidence
Grade C: Emerging Human Data. Early or small human studies exist; results are preliminary and not yet confirmed at scale. Our A-E scale reflects the strength of human evidence, not how popular a compound is.
Sources
- 1.Compounding and the FDA: Questions and Answers · U.S. Food & Drug Administration
- 2.WADA Prohibited List · World Anti-Doping Agency